RxDoctor Payments DataLook up a doctor →

Aaron Mankin, PA

Physician Assistant · Nashville, TNNPI 1295168276

Payments from drug & device makers

$52,566in general payments, 2019–2025

Across 513 payments — averaging $102.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$21K
  • AstraZeneca$20K
  • Pfizer$2K
  • Dendreon Pharmaceuticals LLC$1K
  • Sumitomo Pharma America, Inc.$1K
  • Ferring Pharmaceuticals Inc.$692
  • plus $6K from 33 others

What the payments were for

  • Consulting fees$10,13719%
  • Speaking & faculty fees$24,39546%
  • Travel & lodging$4,7709%
  • Food & beverage$13,01125%
  • Education$2540%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,566 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$213,491
Medicare patients
477
Services billed
10,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide43$651,550
XtandiEnzalutamide39$537,966
OrgovyxRelugolix36$91,185
GemtesaVibegron120$84,638
MyrbetriqMirabegron102$81,781
Abiraterone Acetate14$39,384
Tamsulosin Hcl314$5,209
Finasteride356$5,087
Tolterodine Tartrate ErTolterodine Tartrate12$3,146
NitrofurantoinNitrofurantoin Macrocrystal84$2,901
Trimethoprim54$2,833
Testosterone15$1,849
Solifenacin Succinate11$1,817
Testosterone Cypionate34$1,302
Methenamine Hippurate15$1,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$21,345$651,55043 claims
Astellas Pharma US IncXtandi, Myrbetriq$402$619,747141 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,097$175,824156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →